Literature DB >> 23134540

Elective segmental ureterectomy for transitional cell carcinoma of the ureter: long-term follow-up in a series of 73 patients.

Alchiede Simonato1, V Varca, A Gregori, A Benelli, M Ennas, A Lissiani, M Gacci, S De Stefani, M Rosso, S Benvenuto, G Siena, E Belgrano, F Gaboardi, M Carini, G Bianchi, G Carmignani.   

Abstract

UNLABELLED: What's known on the subject? and What does the study add? Upper Urinary Tract (UUT) Transitional Cell Carcinoma (TCC) is an uncommon disease and represents approximately 5% of all urothelial carcinomas. We report our series on 73 patients treated with Kidney Sparing Surgery for UUT TCC. Good results have been achieved in terms of oncological outcome comparing this conservative approach to the radical nephrourectomy.
OBJECTIVES: • To report the long-term oncological outcome in patients with transitional cell carcinoma of the ureter electively treated with kidney-sparing surgery. • To compare our data with the few series reported in the literature. PATIENTS AND METHODS: • We considered 73 patients with transitional cell carcinoma of the distal ureter treated in five Italian Departments of Urology. • The following surgeries were carried out: 38 reimplantations on psoas hitch bladder (52%), 21 end-to-end anastomoses (28.8%), 11 direct ureterocystoneostomies (15.1%) and three reimplantations on Boari flap bladder (4.1%). • The median follow-up was 87 months.
RESULTS: • Tumours were pTa in 42.5% of patients, pT1 in 31.5%, pT2 in 17.8% and pT3 in 8.2%. • Recurrence of bladder urothelial carcinoma was found in 10 patients (13.7%) after a median time of 28 months. • The bladder recurrence-free survival at 5 years was 82.2%. • The overall survival at 5 years was 85.3% and the cancer-specific survival rate at 5 years was 94.1%.
CONCLUSION: • Our data show that segmental ureterectomy procedures do not result in worse cancer control compared with data in the literature regarding nephroureterectomy.
© 2012 THE AUTHORS. BJU INTERNATIONAL © 2012 BJU INTERNATIONAL.

Entities:  

Mesh:

Year:  2012        PMID: 23134540     DOI: 10.1111/j.1464-410X.2012.11554.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  6 in total

1.  Total ureterectomy and ileal ureteric replacement for TCC ureter in a solitary kidney.

Authors:  John S Banerji; Arun J P George
Journal:  Can Urol Assoc J       Date:  2014-11       Impact factor: 1.862

2.  Long-term outcomes of upper tract urothelial carcinoma: A retrospective evaluation of single-center experience in 275 patients.

Authors:  Mohamed Mohamed Elawdy; Yasser Osman; Diaa Eldin Taha; Samer El-Halwagy; Mohamed Abd El-Hamid; Rasha T Abouelkheir
Journal:  Turk J Urol       Date:  2019-02-05

Review 3.  Risk-adapted strategy for the kidney-sparing management of upper tract tumours.

Authors:  Thomas Seisen; Pierre Colin; Morgan Rouprêt
Journal:  Nat Rev Urol       Date:  2015-02-24       Impact factor: 14.432

Review 4.  Diagnostic challenges and treatment strategies in the management of upper-tract urothelial carcinoma.

Authors:  Victor M Schuettfort; Benjamin Pradere; Fahad Quhal; Hadi Mostafaei; Ekaterina Laukhtina; Keiichiro Mori; Reza Sari Motlagh; Michael Rink; David D'Andrea; Mohammad Abufaraj; Pierre I Karakiewicz; Shahrokh F Shariat
Journal:  Turk J Urol       Date:  2020-10-09

Review 5.  Update of the ICUD-SIU consultation on upper tract urothelial carcinoma 2016: treatment of localized high-risk disease.

Authors:  Georgios Gakis; Tina Schubert; Mehrdad Alemozaffar; Joaquim Bellmunt; Bernard H Bochner; Steven A Boorjian; Siamak Daneshmand; William C Huang; Tsunenori Kondo; Badrinath R Konety; Maria Pilar Laguna; Surena F Matin; Arlene O Siefker-Radtke; Shahrokh F Shariat; Arnulf Stenzl
Journal:  World J Urol       Date:  2016-04-04       Impact factor: 4.226

Review 6.  Risk stratification for upper tract urinary carcinoma.

Authors:  Daniel Benamran; Thomas Seisen; Elias Naoum; Christophe Vaessen; Jérome Parra; Pierre Mozer; Shahrokh F Shariat; Morgan Rouprêt
Journal:  Transl Androl Urol       Date:  2020-08
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.